After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treat...
- Telphone : +1 (905) 787-2041
- Email Address: [email protected]
iHealth Solutions - Moving Forward
Moving Forward